AP2015008675A0 - Peptides and compositions for treatment of joint damage - Google Patents

Peptides and compositions for treatment of joint damage

Info

Publication number
AP2015008675A0
AP2015008675A0 AP2015008675A AP2015008675A AP2015008675A0 AP 2015008675 A0 AP2015008675 A0 AP 2015008675A0 AP 2015008675 A AP2015008675 A AP 2015008675A AP 2015008675 A AP2015008675 A AP 2015008675A AP 2015008675 A0 AP2015008675 A0 AP 2015008675A0
Authority
AP
ARIPO
Prior art keywords
peptides
compositions
treatment
joint damage
damage
Prior art date
Application number
AP2015008675A
Other languages
English (en)
Inventor
Jian Shi
Kristen Johnson
Original Assignee
Novartis Af
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Af filed Critical Novartis Af
Publication of AP2015008675A0 publication Critical patent/AP2015008675A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
AP2015008675A 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage AP2015008675A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201461938123P 2014-02-10 2014-02-10
PCT/US2014/022102 WO2014138687A1 (en) 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage

Publications (1)

Publication Number Publication Date
AP2015008675A0 true AP2015008675A0 (en) 2015-08-31

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008675A AP2015008675A0 (en) 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage

Country Status (39)

Country Link
US (4) US9649359B2 (ru)
EP (2) EP2964250B1 (ru)
JP (3) JP6567429B2 (ru)
KR (1) KR102267341B1 (ru)
CN (2) CN105025917B (ru)
AP (1) AP2015008675A0 (ru)
AU (3) AU2014225348B2 (ru)
BR (2) BR122016021558B1 (ru)
CA (1) CA2903448C (ru)
CL (1) CL2015002443A1 (ru)
CO (1) CO7461145A2 (ru)
CR (2) CR20200290A (ru)
CU (1) CU24301B1 (ru)
CY (1) CY1120729T1 (ru)
DK (1) DK2964250T3 (ru)
EA (1) EA035158B1 (ru)
EC (1) ECSP15042898A (ru)
ES (1) ES2684349T3 (ru)
HK (1) HK1214754A1 (ru)
HR (1) HRP20181269T1 (ru)
HU (1) HUE038499T2 (ru)
IL (1) IL240727B (ru)
JO (1) JO3564B1 (ru)
LT (1) LT2964250T (ru)
MX (1) MX365157B (ru)
MY (1) MY173172A (ru)
NZ (1) NZ711037A (ru)
PE (1) PE20151528A1 (ru)
PH (1) PH12015501983A1 (ru)
PL (1) PL2964250T3 (ru)
PT (1) PT2964250T (ru)
RS (1) RS57446B1 (ru)
SG (1) SG11201506490TA (ru)
SI (1) SI2964250T1 (ru)
TN (1) TN2015000385A1 (ru)
TW (1) TWI634124B (ru)
UY (1) UY35368A (ru)
WO (1) WO2014138687A1 (ru)
ZA (1) ZA201505966B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN00572A (ru) 2009-07-14 2015-06-12 Scripps Research Inst
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
CN109891632A (zh) 2016-10-24 2019-06-14 住友化学株式会社 间隔件、和包含间隔件的二次电池
WO2018087727A1 (en) * 2016-11-14 2018-05-17 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
PE20210406A1 (es) 2018-07-25 2021-03-02 Novartis Ag Inhibidores de inflamasoma nlrp3
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN111973617A (zh) * 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
WO2021001804A1 (en) * 2019-07-04 2021-01-07 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
CN117355323A (zh) 2021-05-24 2024-01-05 诺华股份有限公司 用于治疗骨关节炎的方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
WO2023084388A1 (en) 2021-11-10 2023-05-19 Novartis Ag Methods for determining the biological activity of angptl polypeptides
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
KR20240087877A (ko) * 2022-12-09 2024-06-20 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
CA2361849A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
EP1198568B1 (en) 1999-07-20 2007-07-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2425145C (en) 2000-10-16 2011-08-30 Genentech, Inc. Methods of treatment using wisp polypeptides
US20040249141A1 (en) 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CN1615440A (zh) 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
BR0314172A (pt) 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
MXPA05003978A (es) 2002-10-16 2005-06-22 Scripps Research Inst Sintesis de glicoproteinas.
DE60327369D1 (de) 2002-10-16 2009-06-04 Scripps Research Inst Stellenspezifischer einbau von ketoaminosäuren in proteine
EP1613735B1 (en) 2003-04-17 2012-01-25 The Scripps Research Institute Expanding the eukaryotic genetic code
WO2005007870A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute COMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
US7527943B2 (en) 2003-07-07 2009-05-05 The Scripps Research Institute Compositions of orthogonal glutamyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
JP5192150B2 (ja) 2003-07-07 2013-05-08 ザ スクリプス リサーチ インスティチュート 直交リシルｔＲＮＡとアミノアシルｔＲＮＡシンテターゼの対の組成物及びその使用
WO2006034332A2 (en) 2004-09-21 2006-03-30 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
EP1807515A4 (en) 2004-10-27 2008-06-18 Scripps Research Inst ORTHOGONAL TRANSLATION COMPONENTS FOR IN VIVO INCORPORATION OF NON-NATURAL AMINO ACIDS
CA2601677A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1899457B1 (en) 2005-05-24 2012-09-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
ES2432391T3 (es) 2006-03-09 2013-12-03 The Scripps Research Institute Sistema para la expresión de componentes de traducción ortogonales en células huésped eubacterianas
TWI528964B (zh) 2006-12-06 2016-04-11 生化學工業股份有限公司 治療關節失調之長效藥劑
EA019661B1 (ru) 2006-12-08 2014-05-30 Лексикон Фармасьютикалз, Инк. Моноклональные антитела против angptl3
WO2008098930A1 (en) 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
IN2012DN00572A (ru) * 2009-07-14 2015-06-12 Scripps Research Inst
CA2826142A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
DK2864360T3 (en) 2012-06-25 2017-12-18 Brigham & Womens Hospital Inc TARGETED THERAPY
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
JP2020015725A (ja) 2020-01-30
PT2964250T (pt) 2018-10-19
EP2964250A1 (en) 2016-01-13
US20200268849A1 (en) 2020-08-27
EP2964250B1 (en) 2018-05-16
EA201591661A1 (ru) 2015-12-30
MX365157B (es) 2019-05-24
CL2015002443A1 (es) 2016-05-20
TN2015000385A1 (en) 2017-01-03
CO7461145A2 (es) 2015-11-30
IL240727B (en) 2019-12-31
JP2021178841A (ja) 2021-11-18
CA2903448C (en) 2021-03-23
KR102267341B1 (ko) 2021-06-21
UY35368A (es) 2014-10-31
CU24301B1 (es) 2017-12-08
BR122016021558B1 (pt) 2023-03-28
BR112015021269A2 (pt) 2017-10-10
US10328126B2 (en) 2019-06-25
US20220184182A1 (en) 2022-06-16
PH12015501983B1 (en) 2016-01-11
AU2016277608A1 (en) 2017-01-12
AU2016203028B2 (en) 2017-02-02
PL2964250T3 (pl) 2018-10-31
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
ZA201505966B (en) 2017-03-29
WO2014138687A1 (en) 2014-09-12
CU20150097A7 (es) 2016-05-30
US20170252407A1 (en) 2017-09-07
ECSP15042898A (es) 2019-03-29
ES2684349T3 (es) 2018-10-02
HRP20181269T1 (hr) 2018-10-19
US11179442B2 (en) 2021-11-23
JP2016510763A (ja) 2016-04-11
CN105025917A (zh) 2015-11-04
JO3564B1 (ar) 2020-07-05
RS57446B1 (sr) 2018-09-28
BR112015021269B1 (pt) 2023-04-11
CR20200290A (es) 2020-08-27
IL240727A0 (en) 2015-10-29
AU2016203028A1 (en) 2016-05-26
PH12015501983A1 (en) 2016-01-11
CN105025917B (zh) 2020-08-18
AU2016277608B2 (en) 2018-04-05
KR20150125712A (ko) 2015-11-09
SG11201506490TA (en) 2015-09-29
CA2903448A1 (en) 2014-09-12
DK2964250T3 (da) 2018-08-06
EA035158B1 (ru) 2020-05-06
AU2014225348A1 (en) 2015-09-10
BR122016021558A2 (pt) 2019-07-30
EP3391900A1 (en) 2018-10-24
HK1214754A1 (zh) 2016-08-05
CN111808182A (zh) 2020-10-23
MY173172A (en) 2020-01-02
MX2015011963A (es) 2015-12-09
NZ711037A (en) 2018-07-27
CR20150466A (es) 2015-10-27
HUE038499T2 (hu) 2018-10-29
TW201444865A (zh) 2014-12-01
AU2016203028C1 (en) 2017-06-01
AU2014225348B2 (en) 2016-03-31
TWI634124B (zh) 2018-09-01
LT2964250T (lt) 2018-07-25
CY1120729T1 (el) 2019-12-11
JP6918871B2 (ja) 2021-08-11
US20160008433A1 (en) 2016-01-14
US9649359B2 (en) 2017-05-16
JP6567429B2 (ja) 2019-08-28

Similar Documents

Publication Publication Date Title
HRP20181269T1 (hr) Peptidi i sastavi za liječenje oštećenja zglobova
HK1220980A1 (zh) 用於治療龐貝氏症的方法和組合物
IL286759A (en) Therapeutic methods and preparations
PT2968418T (pt) Preparações derivadas de materiais placentários e produção e utilização das mesmas
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
GB201317005D0 (en) Composition and methods of treatment
HK1224210A1 (zh) 用於治療纖維化的方法和組合物
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
HK1251979A1 (zh) 肽組合物和使用方法
IL244622A0 (en) Preparations for the treatment of hypertension and/or fibrosis
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
IL244621A0 (en) Preparations for the treatment of hypertension and/or fibrosis
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
GB201319255D0 (en) Therapeutic compositions and methods